Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NCI extends Delcath’s cancer therapy work by five years
April 2007
SHARING OPTIONS:

STAMFORD, Conn.—Delcath Systems Inc. recently announced that the company has signed a five-year extension to its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
 
This extension enhances and expands the initial CRADA that expired in December 2006. The new five-year extension provides for Delcath and the NCI to collaborate in the joint development and evaluation of the company's device to deliver high-dose Melphalan to patients, and to evaluate the advisability of developing additional commercial agents for use with the Delcath System, the company's percutaneous perfusion technology for region-specific delivery of chemotherapeutic and other therapeutic agents.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.